Valuation : NetraMark Holdings Inc.

Market Cap 64.35M 46.36M 40.03M 37.9M 34.31M 4.43B 64.8M 450M 173M 2.26B 174M 170M 7.13B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 64.35M 46.36M 40.03M 37.9M 34.31M 4.43B 64.8M 450M 173M 2.26B 174M 170M 7.13B EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 46.38M
+0.65%-0.81%-2.80%+47.48% 3,680B
+0.83%-4.07%-2.45%+971.99% 402B
+1.55%-1.14%-15.75%+20.01% 79.69B
-0.23%+3.89%+62.06%+126.93% 79.43B
+0.05%+0.90%-6.60%-14.88% 76.15B
-1.35%-5.22%-45.81%+172.20% 65.07B
+0.07%-5.21%+2.76%-13.97% 45.49B
-0.69%+0.36%-12.50%+49.26% 40.29B
-1.64%-2.42%+122.17%+252.04% 34.92B
Average -0.08%-1.52%+11.23%+179.01% 500.36B
Weighted average by Cap. +0.59%-1.11%-1.60%+132.63%

Financials

2026 *2027 *
Net sales 401K 289K 249K 236K 214K 27.62M 404K 2.8M 1.08M 14.06M 1.09M 1.06M 44.43M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!